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when considering a α/β ratio of 10. The mean GTV and PTV 
D98% and D50% were 41.6Gy (SD:7.7) and 46.5Gy (SD:6.8) 
,39.3Gy (SD:7) and 46.1Gy (SD:6.6) respectively. Each 
treatment was delivered by an average of 158 beams. All 
dose constraint parameters proposed by Timmerman were 
respected (Semin.Radiat.Oncol.2008). Furthermore, the 
average difference between the Raytracing and the Monte 
Carlo algorithm was 0.43% on these values. At a median 
follow up of 30.9 months (range: 5.7-50.3), the 1 and 2-year 
LC rates remained stable at 83.5%.The 1 and 2-year liver PFS 
and the DFS rates were 57.1%, 46.1% and 75.5%, 64.4% 
respectively. The 2 year OS was 60.6% (Figure 1). No acute 
grade 2 toxicities were observed. Three patients reported 
late grade 2 gastro-intestinal toxicities. No late grade 3 nor 4 
toxicities were reported. 
 
 
 
Conclusion: Robotic SBRT is feasible, safe and very well 
tolerated for the treatment of hepatic oligometastases. Our 
outcome results compare favorably from previous published 
studies of SBRT. It could represent a valid treatment option 
in the multimodality treatment of unresectable hepatic 
oligometastases. 
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Purpose or Objective: Patients with locally advanced 
gallbladder cancer (LAGC) have a dismal prognosis. We 
investigated outcomes and risk factors for overall survival 
(OS) in patients treated with radical surgery and adyuvant 
chemoradiotherapy (CRT). 
 
Material and Methods: A total of 212 patients with LAGC 
[⩾cT3 59% and/or cN+ 52%) were studied. For survival 
outcomes potential associations were assessed in univariate 
and multivariate analyses using the Cox proportional hazards 
model. We constructed a risk scoring system in which points 
were assigned to each risk factor by dividing each ß 
coefficient in the final model by the lowest ß coefficient and 
rounding to the nearest integer. 
 
Results: Median follow-up was 46.2 months (2-235). Five-year 
OS for the entire cohort was 50.2%. In multivariate analysis 
higher pT stage [HR 1.73, p = 0.01], R1 resection [HR 5.06, p 
< 0.01], and number of surgical procedures [HR 1.41, p = 
0.05] were associated with an increased risk of death. A risk 
model was generated to determine a prognostic index for 
individual patients with LAGC. 
 
Conclusion: Overall results after multimodality treatment of 
LAGC are promising. Classification of risk factors for death 
has contributed to propose a prognostic index that could 
allow us to guide risk-adapted tailored treatment 
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Purpose or Objective: To retrospectively review the 
treatment outcome of esophageal cancer in our hospital, and 
compare the radiotherapy efficacy and toxicity of helical 
tomotherapy with step-and-shoot Intensity Modulation 
Radiation Therapy (IMRT). 
 
Material and Methods: Between 2007 and 2012, 108 
consecutive patients with locally advanced esophageal 
cancer, cT2-4N0-3M0-1, received neoadjuvant concurrent 
chemoradiotherapy (CCRT) followed by esophagectomy or 
definitive CCRT treatment course respectively. The 
radiotherapy was delivered with helical tomotherapy in 56 
patients, and with conventional IMRT in other 52 patients. 
We had evaluated outcomes with radiation dose, overall 
survival rate (OS), disease-free survival rate (DFS), and 
toxicity of radiation pneumonitis. 
 
Results: The median follow-up duration was 16 months. The 
median time of overall survival among all patients was 15 
months. The treatment modality with neoadjuvant CCRT 
followed by esophagectomy had favorable OS (47.6% : 
10.4%，p = 0.014), DFS (42.9% : 23.9%，p = 0.013), and local 
recurrence (33.3% : 50.7%，p = 0.574) comparing with 
definitive CCRT. No significant difference outcome of OS was 
found between tomotherapy and conventional IMRT. The 
patients using tomotherapy had less incidence and severity of 
radiation pneumonitis (only one patient with less than grade 
3 radiation pneumonitis in tomotherapy group; 5 patients < 
grade 3 and 2 patients > grade 3 radiation pneumonitis in 
conventional IMRT group). 
 
Conclusion: In our study, the treatment outcomes of 
neoadjuvant CCRT followed by esophagectomy for esophageal 
cancer are better in OS, DFS, and local control than 
definitive CCRT. Tomotherapy may reduce lung dose, and 
probably reduce incidence and severity of radiation 
pneumonitis when compared with conventional IMRT. 
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Purpose or Objective: To evaluate the feasibility and 
efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in 
the treatment of liver metastases from radioresistant primary 
tumors. 
 
Material and Methods: Patients with inoperable liver 
metastases from renal cancers, melanoma and sarcomas, not 
amenable to other locoregional therapies, treated with SABR 
were included in this retrospective study. Inclusion criteria 
were: Karnofsky Performance Status of 70; no evidence of 
progressive or untreated gross disease outside the liver; 
maximum tumor diameter less than 6 cm; no more than 3 
liver lesions; normal liver volume greater than 1000 cm3; 
adequate liver function. Dose prescription ranged from 75 to 
50.26Gy in 3 consecutive fractions, delivered with RapidArc 
VMAT, with 10MV FFF photons. Local control was defined 
according to RECIST criteria.Toxicity was classified according 
to the Common Toxicity Criteria (CTC) version 3.0. 
 
Results: From April 2010 to October 2015, 20 patients were 
treated with SABR for a total number of 24 lesions. Median 
follow-up was 21 (range 6–58) months. In field progression 
was observed in 1 patient for a total of 2 lesions. One and 2 
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years actuarial local control (LC) rates were 100% and 88%, 
respectively. Median overall survival (OS) was 24 months. 
Actuarial OS rates at 1 and 2 years were 83% and 38%, 
respectively. Median progression-free survival (PFS) was 7 
months. No patients experienced radiation-induced liver 
disease (RILD) or grade >3 toxicity. 
 
Conclusion: SABR is an effective, safe and non-invasive 
alternative for the treatment of inoperable liver metastases 
from radioresistant tumor. 
 
Electronic Poster: Clinical track: Lower GI (colon, rectum, 
anus)  
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Purpose or Objective: To compare the clinical outcomes 
between short course chemoradiotherapy (SCRT) and long 
course chemoradiotherapy (LCRT) with delayed surgery for 
locally advanced rectal cancer patients retrospectively. 
 
Material and Methods: Seventy two patients, staged cT3-
4N0-2M0, had participated in a multicenter study. With 
regard to the SCRT arm, a total dose of 25 Gy of radiotherapy 
was delivered in 5 fractions and chemotherapy was given on 
days 1-3 and delivered 5-Fluouracil and Leucovorin 
400mg/m²by bolus injection on day 1 and 5-Fluouracil 
1200mg/m²by continuous infusion on day 2 and 3. And 
additional two cycles of chemotherapy was administered 
before the surgery. With regard to the LCRT arm, a total dose 
of 50.4Gy of radiotherapy was delivered in 28 fractions. 
Chemotherapy was a bolus injection of 5-Fluouracil and 
leucovorin for the first and last week of radiotherapy. 
Surgery was performed during 6 - 8 weeks after completion of 
the radiotherapy in the both group. 
 
Results: From 2010 to 2015, 19 patients were treated using 
the SCRT and 53 patients were treated using the LCRT. 
Median Follow-up was 25.0 months (range, 3.0-58.0 months). 
The patient characteristics of the both arms were not 
significantly different. The sphincter saving rate (89.5 %, 
94.3%), complete remission (21.1%, 13.2%), downstaging 
(47.4%, 26.4%), treatment complications including wound 
dehiscence, bowel adhesion, hematologic toxicities of the 
SCRT were not inferior results to those of the LCRT. 
Locoregional recurrence was seen in 1 (5.3%) patients in the 
SCRT, 1 (1.9%) in the LCRT (p=0.442). Distant metastasis was 
ween in 1 (5.3%) patients in the SCRT, 12 (22.6%) patients in 
the LCRT (p=0.162). The 2-year disease free survival, overall 
survival in the SCRT and LCRT arms were 93.8% and 74.0% (P 
=0.338), 90.0% and 91.2% (P =0.448), respectively. 
 
Conclusion: The preopeative SCRT was a effective and safe 
modality. We got a comparable clinical outcomes to the LCRT 
for locally advanced rectal cancer. We get a further study for 
randomized clinical study to compare between SCRT and 
LCRT.  
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Purpose or Objective: Preoperative chemoradiation for 
rectal cancer may cause acute bowel toxicity. Efforts to 
reduce such side effects include tracking bowel DVH 
relationships and proper patient positioning to minimize the 
risks. Our aim is to quantify volume and DVH relationship 
differences between prone and supine positioning as well as 
compare different contouring methods to account for such 
changes. 
 
Material and Methods: Nineteen patients undergoing 
preoperative chemoradiation for rectal cancer were 
simulated supine and prone for plan comparison. Thirty-eight 
plans were compared, 19 prone, and 19 supine. Correlating 
prone and supine plans were constructed with similar target 
volumes, beam energies and arrangements. A single physician 
contoured the bowel bag (BB) and individual bowel loops (BL) 
with the superior border 1 cm above the PTV per RTOG 
guidelines. If the RTOG recommended boundaries fell short of 
the 5 Gy isodose line, additional CT slices were contoured on 
BB and BL structures to the 5 Gy isodose line and labeled as 
extended contours. Tabular dose-volume histograms were 
utilized to assess the volume of bowel receiving 5-50 Gy in 5 
Gy intervals. Wilcoxon signed rank test as well as Spearman’s 
correlation tested all variables. 
 
Results: The target volumes showed no statistical differences 
between supine and prone positioning (p = 0.7344, 0.8203, 
0.3594). The median reduction in volumes from supine to 
prone contours for the extended contour BB, extended 
contour BL, RTOG BB, and RTOG BL was 316 cc, 156 cc, 324 
cc, and 115 cc respectively. Wilcoxon signed rank sum test 
showed significantly reduced volumes at each dose level (5-
45 Gy at 5 Gy intervals) in the prone group compared to 
supine (range p = 0.0039- 0.0391). All combinations of 
contours (RTOG and extended contours of BB and BL) showed 
similar statistically significant reductions in volumes 
receiving each dose (except 50 Gy) in the prone position. All 
RTOG defined BB and BL volumes required additional 
contours to account for the entire volume receiving 5 Gy. 
RTOG contours required a median of 359 cc to the BB (range 
209-1375 cc) and 113 cc to BL (range 37-271 cc). 
 
Conclusion: Volume of bowel was less for nearly all dose 
levels (5 – 45 Gy) if the patient was positioned prone. Bowel 
loop contours correlated with bowel bag contours; suggesting 
they can be used interchangeably. BB and BL contoured 
volumes, by the RTOG definition, consistently fell short of 
the 5 Gy isodose line where the “extended contours” were a 
more complete DVH representation. 
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Purpose or Objective: The standard treatment for locally 
advanced rectal cancer (LARC) is preoperative 
chemoradiotherapy (CRT) followed by total mesorectal 
excision (TME). The tumoral response to CRT is highly 
heterogeneous and about 15-30% of the patients achieve a 
pathological complete response (pCR). 18F-FDG PET/CT is 
